It is necessary to identify compounds that may provide protection against alcoholic liver disease. To the best of our knowledge, the effect of myricitrin on the development of ethanol-induced liver disease has not been previously investigated. The present study aimed to determine the effect of myricitrin on ethanol-induced steatosis in AML12 mouse liver cells and to identify the underlying molecular mechanisms. Ethanol-treated AML12 cells exhibited significant improvement in viability following treatment with myricitrin. Oil red O staining indicated that myricitrin ameliorated ethanol-induced lipid accumulation in cells. Furthermore, following treatment with myricitrin, improvement in ethanol-induced steatosis and decrease in the levels of reactive oxygen species and lipoperoxides were observed in ethanol-stimulated cells. Myricitrin suppressed mRNA and protein expression of tumor necrosis factor-α, interleukin-6 and transforming growth factor-β1 in ethanol-stimulated AML12 cells. Myricitrin markedly increased phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and significantly reduced mRNA expression of sterol-regulatory element-binding protein-1c (SREBP-1c) and fatty acid synthase in ethanol-stimulated AML12 cells. The results of the present study indicate that myricitrin ameliorates ethanol-induced steatosis in AML12 cells by attenuating oxidative stress, suppressing expression of certain inflammatory cytokines and modulating the AMPK/SREBP-1c pathway.
Introduction
Alcoholic liver disease (ALD) is a worldwide health concern. The World Health Organization states that there are 3.3 million alcohol-associated mortalities each year (1) . Excessive alcohol consumption can lead to acute and chronic fatty liver diseases, including steatosis, alcoholic hepatitis, liver fibrosis, liver cirrhosis and hepatocellular carcinoma (2) . Steatosis occurs during the early stage of ALD and is characterized by excessive fat accumulation in hepatocytes (3) . There are numerous mechanisms underlying fat accumulation, including de novo lipogenesis, impaired β-oxidation of fatty acids and uptake of triglyceride-rich lipoproteins (4) (5) (6) . Furthermore, previous studies have demonstrated that ethanol-induced oxidative stress and associated production of cytokines have a role in the development of ALD (7, 8) .
Benign steatosis can be reversed by abstinence from alcohol; however, there are currently no effective clinical approaches for the treatment of ALD (2, 3) . Thus, it is necessary to identify compounds that may provide protection against ALD. Myricitrin (3' ,4' ,5' ,5,7-five hydroxyflavone-3-O-α-L-rha mnoside), a naturally occurring polyphenol hydroxy flavonoid present in a number of berries, vegetables and various edible and/or medicinal herbs, has been reported to exhibit a variety of beneficial properties, including anti-inflammatory, antinociceptive, anticarcinogenic and antimicrobial activities (9) (10) (11) (12) (13) . Myricitrin exhibits oxidative resistance and free radical scavenging activities due to its polyhydroxy structure (14) . Myricitrin has been reported to suppress acrylamide-mediated cytotoxicity in human Caco-2 cells by inhibiting the production of reactive oxygen species (ROS) (15) . Shimosaki et al (13) confirmed that pretreatment with high-performance liquid chromatography-purified myricitrin from Myrica extract can inhibit production of tumor necrosis factor-α (TNF-α) in lipopolysaccharide-stimulated RAW264.7 macrophages. Myricitrin inhibits oxidative stress-induced endothelial (16, 17) . It has been demonstrated that myricitrin exhibits anti-oxidative, anti-inflammatory and antifibrotic effects in carbon tetrachloride-intoxicated mice (18) . Myricitrin decreased hepatic lipid peroxidation, increased levels of glutathione, reduced cyclooxygenase-2 and TNF-α overexpression, and inflammation in the liver, and inhibited hepatic expression of transforming growth factor-β1 (TGF-β1) and liver fibrosis (18) . The above studies demonstrated anti-oxidative and anti-inflammatory activities of myricitrin under various disease conditions. However, little is known about the protective effect of myricitrin against alcoholic liver disease. The aim of the present study was to evaluate the effect of myricitrin on ethanol-induced steatosis in mouse AML12 liver cells and to identify possible underlying molecular mechanisms.
Materials and methods
Cell culture. AML12 mouse liver cells were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle medium/nutrient mixture F12 (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) containing 100 units/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum (Hyclone; GE Healthcare Life Sciences) at 37˚C in an incubator with 5% CO 2 .
Cell viability. Cell viability was assessed by an MTT assay. Briefly, AML12 cells were seeded in 96-well plates at the density of 1x10 4 cells/well. The following day, cells were treated with 800 mM ethanol and co-cultured with 5, 10, 20 or 40 µM myricitrin for 16 h. Subsequently MTT solution (5 mg/ml) was added to each well and the cells were cultured for another 4 h. MTT formazan precipitate was dissolved in dimethyl sulfoxide (DMSO) and the absorbance was measured at a wavelength of 570 nm using a microplate reader (Varioskan Flash; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The vehicle control cells were treated with ultrapure water rather than ethanol, and DMSO rather than myricitrin. Cell viability values are expressed as percentage of the vehicle control (100%). All experiments were performed in triplicate.
Oil red O staining. AML12 cells were seeded into 24-well plates at a density of 1x10 5 /well. The following day, cells were stimulated with 100 mM ethanol and co-treated with 20 µM myricitrin. Following 36 h of treatment, cells were washed with ice-cold PBS buffer, fixed with 10% formalin at room temperature for 10 min, and stained with oil red O at room temperature for 30 min to detect lipid droplets in cells. Following staining, the cultures were washed and the dye was extracted by isopropanol. Quantification was performed by measuring optical density at a wavelength of 510 nm. Cell lipid peroxidation assay. AML12 cells were plated and treated with ethanol and myricitrin as described above. At 48 h after ethanol and myricitrin treatment, total lipoperoxides were measured as thiobarbituric acid reactive substances (TBARS) in culture medium using a Lipid Peroxidation MDA Assay kit (Beyotime Institute of Biotechnology, Haimen, China), according to the manufacturer's protocol. TBARS were quantified using malondialdehyde (MDA) present in each sample.
Determination of cytokine secretion in ethanol-intoxicated cell culture. AML12 cells were plated and treated with ethanol and myricitrin as described above. A total of 48 h after ethanol and myricitrin treatment, the cells were centrifuged at 400 x g at 4˚C for 5 min, the supernatant was collected and samples were stored at -20˚C until cytokine levels were measured. The concentrations of TNF-α, interleukin (IL)-6 and TGF-β1 in cell supernatants were tested using the following ELISA kits: TNF-α (cat. no. ml002095), IL-6 (cat. no. ml002293) and TGF-β1 (cat. no. ml002115). All kits were purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd. (Shanghai, China), and performed according to the manufacturer's protocol.
Quantitative analyses of mRNA expression by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was isolated from AML12 cells using the TRIpure reagent (Roche Applied Science, Mannheim, Germany) according to the manufacturer's protocol. cDNA was synthesized from hepatic mRNA using RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.). The following temperature protocol was used for cDNA synthesis: Incubation for 5 min at 25˚C, followed by 60 min at 42˚C and then termination of the reaction via incubation for 5 min at 70˚C. Hepatic sterol regulatory element binding protein-1c (SREBP-1c), fatty acid synthase (FAS), TNF-α, IL-6, and TGF-β1 were analyzed using specific primers listed in Table I Statistical analysis. All data were processed and analyzed using GraphPad software (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA) and are presented as the mean ± standard error of the mean. One-way analysis of variance with Bonferroni's multiple comparison test were used for analyses. P<0.05 was considered to indicate a statistically significant difference. 
Results

Myricitrin exerts a protective effect against ethanol-induced
Myricitrin reduces ethanol-induced oxidative stress and decreases mRNA expression of certain cytokines in AML12 cells.
Oxidative stress is reported to be involved in the development of ethanol-induced steatosis (2) . The present study investigated the effect of myricitrin treatment on MDA and ROS production in AML12 cells. Treatment with myricitrin resulted in a 32.1% decrease in ROS levels (P<0.001) and 22.4% decrease in MDA levels (P<0.001) in ethanol-stimulated AML12 cells (Fig. 3) . The above data indicate that myricitrin Table I . Primer sequences used for amplification of mRNA by quantitative polymerase chain reaction. alleviates ethanol-induced oxidative stress in liver cells. Certain pro-inflammatory cytokines, including TNF-α, IL-6 and TGF-β1 have been reported to be associated with the development of ethanol-induced hepatic steatosis (8, 22) . Expression levels of TNF-α, IL-6 and TGF-β1 were also been determined in the present study. Cells stimulated with ethanol exhibited markedly elevated mRNA expression levels of TNF-α, compared with control cells (Fig. 4A) . However, ethanol-induced increase in TNF-α mRNA levels was significantly attenuated in cells treated with myricitrin (47.9%; P<0.001). Similarly, cells stimulated with ethanol exhibited markedly increased expression of IL-6 and TGF-β1 mRNA compared with control cells. This ethanol-induced elevation of mRNA levels of IL-6 and TGF-β1 was significantly attenuated, by 27.1% (P<0.01) and 51.8% (P<0.001) respectively, in cells treated with myricitrin. Furthermore, ethanol-induced secretion of TNF-α, IL-6 and TGF-β1 proteins was also suppressed by 28.3% (P<0.01), 44.6% (P<0.05) and 43.8% (P<0.01), respectively, in cells treated with myricitrin (Fig. 4B) .
Primer sequence (5'-3') ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The results suggest that myricitrin may reduce oxidative stress and affect the production of pro-inflammatory cytokines to prevent ethanol-induced steatosis in AML12 liver cells.
Myricitrin activates AMPK and reduces the ethanol-induced elevation of SREBP-1c and FAS mRNA expression in AML12
cells. Previous studies indicated that AMPK inactivation may be involved in the development of ethanol-induced hepatic steatosis (23, 24) . To determine the mechanism underlying myricitrin-induced amelioration of ethanol-induced steatosis, the present study investigated the effect of treatment with myricitrin on AMPK activity. pAMPK protein expression levels in ethanol-stimulated AML12 cells treated with myricitrin increased compared with myricitrin untreated ethanol-stimulated cells, indicating that myricitrin treatment activated AMPK in ethanol-stimulated AML12 cells (Fig. 5A) . 
Discussion
Previous studies have demonstrated that myricitrin may protect against liver injury by attenuating oxidative stress in CCl 4 -intoxicated mice (18) . In the present study, myricitrin suppressed ethanol-induced production of MDA and ROS in mouse AML12 liver cells. The results of the present study further indicate that myricitrin may attenuate oxidative stress in chemically intoxicated cells. Oxidative stress has been hypothesized to serve a role in pathogenesis of ALD (2). The results of the present study suggest that myricitrin may protect against ALD by attenuating oxidative stress. The incidence and development of alcoholic liver disease are associated with overexpression of a number of cytokines, including TNF-α, IL-6 and TGF-β1 (8, 27, 28) . Previous studies have demonstrated that expression of the inflammatory cytokine TNF-α is elevated in patients with alcoholic liver disease (8, 29) . TNF-α has been reported to induce hepatic steatosis in mice by affecting hepatic lipogenic metabolism (30) . Other studies have indicated that expression of IL-6 is elevated in patients with alcoholic liver diseases (27, 28) . Persistent activation of IL-6 signaling may be detrimental to the liver and may cause liver tumors (31) . The present study demonstrated that myricitrin may reduce mRNA expression of TNF-α, IL-6 and TGF-β1, indicating that alleviation of ethanol-induced steatosis in liver cells caused by myricitrin may be partially due to inhibition of ethanol-induced overexpression of TNF-α, IL-6 and TGF-β1 mRNA.
AMPK has a role in cellular energy homeostasis (32) . Inhibition of AMPK suppresses fatty acid oxidation and stimulates lipogenesis (33) . Ethanol has been reported to inhibit AMPK activity in vitro (24) and in vivo (34) . Inhibition of AMPK by ethanol has a role in the development of hepatosteatosis induced by alcohol consumption (23, 24) . SREBP-1c is a regulator of hepatic lipid metabolism and is involved transcription of a number of genes involved in liver triglyceride and fatty acid synthesis, such as FAS (35) (36) (37) . Increased expression of SREBP-1c induced by ethanol may cause hepatic lipid accumulation in alcoholic fatty liver (24) . AMPK activators have been demonstrated to reduce the expression of SREBP-1c (24) . In the present study, myricitrin activated AMPK in ethanol-stimulated AML12 liver cells. The results also demonstrated that myricitrin suppressed mRNA expression of SREBP-1c and FAS. Suppression of SREBP-1c expression and activation of AMPK were observed in ethanol-induced cells following treatment with myricitrin. The results of the present study indicate that myricitrin regulates the AMPK/SREBP-1c signaling pathway and reduces lipid formation in liver cells. However, specific inhibitors or gene specific-short hairpin RNAs may be used in the future to alter the activity of AMPK following treatment with myricitrin to further validate the specificity of myricitrin to the AMPK/SREBP signaling pathway.
Aldose reductase (AKR1B1) is an enzyme that catalyzes the reduction of glucose to sorbitol with the aid of co-factor NADPH in the polyol pathway (38) . We previously reported that AKR1B1 inhibitor ameliorates ethanol-induced steatosis in vitro and in vivo by activating AMPK and suppressing expression of SREBP-1c and FAS (21, 25) . Myricitrin is an inhibitor of AKR1B1 (39, 40) . In the present study, myricitrin ameliorated ethanol-induced steatosis via activation of AMPK and suppression of expression of SREBP-1c and FAS, thus indicating that the beneficial effect of myricitrin on ethanol-induced steatosis may be at least partially attributable to inhibition of AKR1B1.
In conclusion, myricitrin ameliorated ethanol-induced lipid abnormalities in AML12 liver cells, which was partially due to suppression of ethanol-induced oxidative stress and associated with suppression of ethanol-induced overexpression of certain cytokines. The present study also demonstrated that myricitrin activated AMPK and suppressed SREBP-1c and FAS mRNA overexpression to alleviate the development of hepatic steatosis. The present study may provide theoretical basis for therapeutic use of AKR1B1 inhibitor in the treatment of fatty liver disease.
